RegWardenFDA facility compliance records
Recall

Class II — Biocare Medical, LLC

Recalling firmBIOCARE HOLDINGS, LLC
Registered facilityBIOCARE MEDICAL, LLC (the firm's only registered facility)
ClassificationClass II
StatusTerminated
ReasonImmunohistochemistry device kits found to display incorrect staining pattern due to mislabeling of two components.
ProductURO-3 Triple Stain (CD44 + p53) with CK20, Catalog #: PM370TSAA, Package Type: Bag, which contains components: a) CD44 + p53, Catalog #: PM373DSAA, Package Type: Bottle, and b) CK20, Catalog #: PM062AA, Package Type: Bottle Product Usage: URO-3 Triple Stain (CD44 + p53) with CK20 is a cocktail of mouse monoclonal and rabbit monoclonal antibodies that is intended for laboratory use in the qualitative identification of CD44, p53 and CK20 proteins by immunohistochemistry (IHC) in formalin-fixed paraffin-embedded (FFPE) human tissues, primarily for bladder cancer characterization. The clinical…
Quantity11
DistributionWorldwide Distribution - Unites States Nationwide in the states of NY AND FL and the countries of: Morocco and Italy
Initiated2018-03-15
Classified2018-09-19
Terminated2020-04-22
Recall numberZ-3198-2018
InitiationVoluntary: Firm initiated

Source: U.S. FDA via openFDA (opens in a new tab) (device registration & enforcement). Data as of 2026-10-06. Verify this recall record at FDA → (opens in a new tab)

Cite this record

RegWarden. “Class II recall — Biocare Medical, LLC (Z-3198-2018).” Compiled from U.S. FDA public records (openFDA; FDA Data Dashboard). Data as of 2026-10-06. https://regwarden.com/recall/80407/

Not open yet

Alerts for BIOCARE HOLDINGS, LLC

Watchlist alerts will email you when FDA publishes a new recall, inspection classification, or warning letter for a facility you follow. They aren't open to the public yet — leave your email and we'll tell you when they are.

Planned

Want a one-page facility brief?

A single-page summary of this facility's registration and recall history for diligence. Not selling it yet — register interest and we'll follow up.